Revenue Breakdown
Composition ()
No data
Revenue Streams
Biodexa Pharmaceuticals PLC (BDRX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial, accounting for 111.0% of total sales, equivalent to £3.68M. Another important revenue stream is Pipeline R&D. Understanding this composition is critical for investors evaluating how BDRX navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Comparative Benchmarking
In the context of the broader market, BDRX competes directly with industry leaders such as HELP and CDT. With a market capitalization of $1.56M, it holds a significant position in the sector. When comparing efficiency, BDRX's gross margin of N/A stands against HELP's N/A and CDT's N/A. Such benchmarking helps identify whether Biodexa Pharmaceuticals PLC is trading at a premium or discount relative to its financial performance.
